DBV Technologies S.A. American Depositary Shares DBVT

$9.02 -4.25% at last close
Market Cap$566.82 million
P/E Ratio—
Div Yield—
Volume156.5K
52-Week Range $8.63$26.18

Analyst Ratings

Consensus
Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
Avg. Price Target
$45.25 (+401.7% upside)

Full DBVT forecast & analyst actions →

Key Stats

Today's Range
$9.00 – $9.47
50-Day Range
$8.63 – $12.73
52-Week Range
$8.63 – $26.18
Volume
156K shs
Average Volume
359K shs
Market Cap
$566.82 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
1.06%
Days to Cover
4.17

About DBV Technologies S.A. American Depositary Shares

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
179
Exchange
XNAS
Listed
2014-10-22

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.